James Bown
Overview
Explore the profile of James Bown including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
101
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ozcelik F, Dundar M, Yildirim A, Henehan G, Vicente O, Sanchez-Alcazar J, et al.
Funct Integr Genomics
. 2024 Aug;
24(4):138.
PMID: 39147901
Artificial intelligence (AI) platforms have emerged as pivotal tools in genetics and molecular medicine, as in many other fields. The growth in patient data, identification of new diseases and phenotypes,...
2.
Khalil H, Langdon S, Goltsov A, Soininen T, Harrison D, Bown J, et al.
Oncotarget
. 2016 Oct;
7(46):75874-75901.
PMID: 27713148
Nuclear erythroid related factor-2 (NRF2) is known to promote cancer therapeutic detoxification and crosstalk with growth promoting pathways. HER2 receptor tyrosine kinase is frequently overexpressed in cancers leading to uncontrolled...
3.
Khalil H, Langdon S, Kankia I, Bown J, Deeni Y
Oxid Med Cell Longev
. 2016 Jan;
2016:4148791.
PMID: 26770651
NF-E2 related factor-2 (NRF2) is an essential transcription factor for multiple genes encoding antioxidants and detoxification enzymes. NRF2 is implicated in promoting cancer therapeutic resistance by its detoxification function and...
4.
Khalil H, Goltsov A, Langdon S, Harrison D, Bown J, Deeni Y
J Biotechnol
. 2014 Dec;
202:12-30.
PMID: 25449014
Cells are constantly exposed to Reactive Oxygen Species (ROS) produced both endogenously to meet physiological requirements and from exogenous sources. While endogenous ROS are considered as important signalling molecules, high...
5.
Goltsov A, Deeni Y, Khalil H, Soininen T, Kyriakidis S, Hu H, et al.
Cells
. 2014 Jun;
3(2):563-91.
PMID: 24918976
The receptor tyrosine kinases (RTKs) are key drivers of cancer progression and targets for drug therapy. A major challenge in anti-RTK treatment is the dependence of drug effectiveness on co-expression...
6.
Goltsov A, Langdon S, Goltsov G, Harrison D, Bown J
Front Oncol
. 2014 Feb;
4:13.
PMID: 24551596
Drug resistance, de novo and acquired, pervades cellular signaling networks (SNs) from one signaling motif to another as a result of cancer progression and/or drug intervention. This resistance is one...
7.
Bown J, Andrews P, Deeni Y, Goltsov A, Idowu M, Polack F, et al.
Curr Drug Targets
. 2012 Sep;
13(12):1560-74.
PMID: 22974398
Computer simulation can be used to inform in vivo and in vitro experimentation, enabling rapid, low-cost hypothesis generation and directing experimental design in order to test those hypotheses. In this...
8.
Savage A, Katz E, Eberst A, Falconer R, Houston A, Harrison D, et al.
Dis Model Mech
. 2012 Aug;
6(1):252-60.
PMID: 22888098
In cancer, morphological assessment of histological tissue samples is a fundamental part of both diagnosis and prognosis. Image analysis offers opportunities to support that assessment through quantitative metrics of morphology....
9.
Goltsov A, Faratian D, Langdon S, Mullen P, Harrison D, Bown J
Cell Signal
. 2011 Oct;
24(2):493-504.
PMID: 21996585
Systems biology approaches that combine experimental data and theoretical modelling to understand cellular signalling network dynamics offer a useful platform to investigate the mechanisms of resistance to drug interventions and...
10.
Goltsov A, Faratian D, Langdon S, Bown J, Goryanin I, Harrison D
Cell Signal
. 2010 Oct;
23(2):407-16.
PMID: 20951800
Overcoming de novo and acquired resistance to anticancer drugs that target signaling networks is a formidable challenge for drug design and effective cancer therapy. Understanding the mechanisms by which this...